Table 2.

Current immune combination therapy trials in NSCLC.

Drugs	Trials	Pathological Type	Details	Endpoint	Ref.
Immunotherapy + Chemotherapy	KEYNOTE-021G	NSCLC	Pembrolizumab + Platinum-doublet chemotherapy vs. Platinum-doublet chemotherapy	ORR: 55% vs. 29%	[38]
	KEYNOTE-189	NS-NSCLC	Pembrolizumab + Pemetrexed-platinum vs. Placebo + Pemetrexed-platinum	Two-year Median OS: 22.0 months vs. 10.7 months	[39]
	KEYNOTE-407	Squamous NSCLC	Pembrolizumab + Carboplatin and paclitaxel vs Placebo + Carboplatin and paclitaxel	Two-year Median OS: 17.1 months vs. 11.6 months	[40]
	IMpower130	NS-NSCLC	Atezolizumab + Carboplatin plus nab-paclitaxel vs Carboplatin plus nab-paclitaxel	Median OS: 18.6 months vs. 13.9 months	[41]
	IMpower131	Squamous NSCLC	Atezolizumab + Carboplatin plus nab-paclitaxel vs. Carboplatin plus nab-paclitaxel	Median PFS: 6.3 months vs. 5.6 months	[42]
	IMpower132	NS-NSCLC	Atezolizumab + Pemetrexed vs. Pemetrexed	Median PFS: 7.6 months vs. 5.2 months	[43]
	SAKK 16/14	NSCLC	Durvalumab plus Cisplatin and docetaxel	One-year EFS rate: 73%	[44]
	NCT03607539	NS-NSCLC	Sintilimab plus Pemetrexed and platinum vs. Placebo plus Pemetrexed and platinum	Median PFS: 8.9 months vs. 5.0 months	[45]
Immunotherapy + Radiotherapy	NCT02221739	NSCLC	Ipilimumab and Radiotherapy	ORR: 18%	[49]
	NCT02125461	NSCLC	Durvalumab + Chemoradiotherapy vs. Chemoradiotherapy	Two-year OS rates: 66.3% vs. 55.6%	[33]
	NCT02492568 and NCT02444741	NSCLC	Pembrolizumab + Radiotherapy vs. Pembrolizumab	Two-year Median OS: 19.2 months vs. 8.7 months	[50]
Dual Immunotherapy	CheckMate 012	NSCLC	Nivolumab (every 2 week) + Ipilimumab (every 12 week) vs. Nivolumab (every 2 week) + Ipilimumab (every 6 week)	ORR: 47% vs. 38%	[56]
	CheckMate 568	NSCLC	Nivolumab + Ipilimumab	ORR: 30%	[57]
	NCT02477826	NSCLC	Nivolumab + Ipilimumab vs. Platinum doublet chemotherapy	Median OS:17.1 months vs. 13.9 months	[58]
	CheckMate 9LA	NSCLC	Nivolumab + Ipilimumab vs. Platinum doublet chemotherapy	Median OS:14.1 months vs. 10.7 months	[59]
Immunotherapy + Targeted therapy	NCT04203485	NS-NSCLC	Camrelizumab + Apatinib	ORR: 30.9%	[65]
	NCT02501096	NSCLC	Pembrolizumab + Lenvatinib	ORR: 33.0%	[66]
Immunotherapy + Anti-Angiogenic Therapy	NCT03628521	NSCLC	Sintilimab + Anlotinib	ORR: 72.7%	[77]
	IMpower150	NS-NSCLC	ABCP vs BCP	Median OS: 19.2 months vs. 14.7 months	[80]

Abbreviations: NSCLC, non-small cell lung cancer; NS-NSCLC, non-squamous non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; EFS, event-free survival; ORR, objective response rate; BCP, bevacizumab plus carboplatin plus paclitaxel; ABCP, atezolizumab plus bevacizumab plus carboplatin plus paclitaxel.